RAC - Charts & Price Action, page-11916

The key word in your whole post is potential and I’m glad you disclosed that because it is important to remember that Biotech companies are based on the potential of their products until they are commercialised and start making $$.

I do not dispute that the drug has potential but in my opinion and as represented by the market, the company is overvalued based on the IP they have and investors have taken their money out of the stock because they believe it can be put to better use elsewhere. Investors cashing-in on their Biotechs and redirecting elsewhere is not unique to RAC but it certainly seems to be pedalling backwards quicker than the others lately.